STUDY PROTOCOL

Infectious diseases data observatory (IDDO) visceral leishmaniasis library of clinical therapeutic studies: A protocol for a living systematic review of clinical studies

[version 1; peer review: 1 approved with reservations]

Sauman Singh-Phulgenda, Sumayyah Rashan, Eli Harriss, Prabin Dahal, Caitlin Naylor, Matthew Brack, Philippe J. Guerin, Brittany J. Maguire

1Infectious Diseases Data Observatory – IDDO, Oxford, OX3 7LG, UK
2Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, New Richards Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7LG, UK
3The Knowledge Centre, Bodleian Health Care Libraries, University of Oxford, Oxford, OX3 7DQ, UK

Abstract

Introduction: Visceral leishmaniasis (VL) is a vector-borne disease caused by protozoan parasites of the genus Leishmania. The disease is endemic in parts of South Asia, East Africa, South America and the Mediterranean region, with an estimated 50,000 to 90,000 cases occurring annually. A living systematic review of existing scientific literature is proposed to identify clinical drug efficacy studies against VL, conducted following the Preferred Reporting Items for Systematic-Reviews and Meta-Analyses (PRISMA) guidelines.

Methods and analysis: The proposed living systematic review builds on a previous systematic review first carried out in 2016, and the current protocol is designed to capture any published or registered VL clinical study from Nov-2021 onwards. The following databases will be searched by a medical librarian: PubMed, Ovid Embase, Scopus, Web of Science Core Collection, Cochrane Central Register of Controlled Trials, clinicaltrials.gov, WHO ICTR, as well as IMEMR, IMSEAR, and LILACS from the WHO Global Index Medicus. The systematic review will consider both randomised and non-randomised interventional studies, including single-arm studies.

Ethics and dissemination: A database of eligible studies, including study characteristics, is openly available (https://www.iddo.org/tool/vl-surveyor) and will be continually updated every six months. All findings will be published in a peer-reviewed journal.

PROSPERO registration: CRD42021284622 (29/11/2021)
Keywords
Visceral Leishmaniasis, Kala-azar, Living systematic review, data repository

Corresponding author: Sauman Singh-Phulgenda (sauman.singh@iddo.org)

Author roles: Singh-Phulgenda S: Conceptualization, Project Administration, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; Rashan S: Validation, Writing – Review & Editing; Harriss E: Methodology, Validation, Writing – Review & Editing; Dahal P: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; Naylor C: Project Administration, Writing – Review & Editing; Brack M: Project Administration, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; Guerin PJ: Conceptualization, Funding Acquisition, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; Maguire BJ: Conceptualization, Methodology, Project Administration, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by Wellcome [208378; a biomedical grant to the Infectious Diseases Data Observatory, recipient: PJG]. The funders had no role in the design and analysis of the research or the decision to publish the work.

Copyright: © 2022 Singh-Phulgenda S et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Singh-Phulgenda S, Rashan S, Harriss E et al. Infectious diseases data observatory (IDDO) visceral leishmaniasis library of clinical therapeutic studies: A protocol for a living systematic review of clinical studies [version 1; peer review: 1 approved with reservations] Wellcome Open Research 2022, 7:155 https://doi.org/10.12688/wellcomeopenres.17739.1

First published: 18 May 2022, 7:155 https://doi.org/10.12688/wellcomeopenres.17739.1
**Introduction**

Visceral leishmaniasis (VL), also known as kala-azar, is a neglected disease caused by protozoan parasites of the genus *Leishmania*. The disease is endemic in parts of the Indian subcontinent, East Africa, South America and the Mediterranean region, with an estimated 50,000 to 90,000 cases occurring in 2019.

If untreated, the disease is generally fatal within 2 years. Historically, pentavalent antimony (PA) had been the mainstay drug for VL treatment in South Asia. Due to the emergence and evolution of drug-resistant parasites and the poor safety profile of PA at higher doses, single-dose Liposomal Amphotericin B (L-AmB) has been recommended as the first-line therapy in the Indian subcontinent since 2010. PA remains the first-line therapy in East Africa – mainly as a combination regimen with paromomycin as (drug resistance has not been reported and single-dose L-AmB was found to have lower efficacy in this region). Such heterogeneity in therapeutic responses has been thought to arise due to regional differences in parasite sensitivity/susceptibility, differences in underlying patient population, and genetic variability in parasite populations, although to date the exact reasons remain unclear. A consolidation of evidence from existing therapeutic studies can provide further insights into host, parasite and drug determinants of drug resistance or treatment failure. Some major challenges towards such evidence consolidation include: VL studies are generally small and sparse with a median sample size of 32 (range: 1–3,126) patients per treatment arm (See S1 Data in 12). VL control programmes are severely underfunded, and the drug supply is substantially lower than the estimated case burden of VL in several endemic countries, and little is known on the therapeutic efficacy of the existing drug regimens in pregnant patients. It is therefore important to establish a robust and reliable repository of historical studies that can allow pooling data across available clinical trials to maximise the research potential and consequently the impact.

The Infectious Diseases Data Observatory (IDDO) VL library of clinical studies is an open-access resource that provides a systematically assembled inventory of published therapeutic studies. The IDDO VL library was first initiated in 2016 by searching the published literature from 1980 until 2016. After revising the search strategies adopted in 2019, the library has been updated bi-annually and the current approach taken to maintain the IDDO library of clinical studies follows a living systematic review methodology. A living systematic methodology is a periodic and incremental addition to a systematic review which saves resources and time that would be required to plan and conduct a new systematic review from scratch, minimising duplication and inefficiency. Constantly identifying and adding information from new studies to the existing pool thus ensures that any subsequent meta-analysis is based on an updated and robust database. This easily and freely accessible repository allows the selection of studies for inclusion in meta-analyses based on factors such as drug class, geography, and a number of host and parasite characteristics.

After the completion of the search update, the compiled database of eligible studies is made publicly available to the global research community through the VL-surveyor on the IDDO website – which serves as a global “knowledge commons”. Such an inventory can provide a unique resource to the VL research community for a better understanding of historical data on drug safety and efficacy, for planning aggregate data meta-analysis, to assess the potential volume of data available for subsequent data re-use, to assess the feasibility of carrying out individual participant data meta-analysis (IPD-MA) on a specific research topic, and help designing better prospective clinical trials.

This prospective protocol describes the living systematic review methodology used by IDDO to achieve the overarching aim of maintaining the VL library of clinical studies. The research objectives are:

1. **The primary objective of this systematic review is to index all the clinical studies describing the efficacy of antileishmanial therapies and summarise the landscape of the clinical studies**
2. **For all studies included in the living systematic review, the secondary objective is to extract key characteristics and study details of the indexed clinical studies including, study design, outcome measures and patient characteristics.**
3. **The final objective planned for the next living systematic review update is to conduct a meta-analysis on the proportion of patients who develop relapse following VL treatment. Further meta-analyses on other endpoints of interest are anticipated following future search updates.**

**Material and methods**

A systematic review of the existing scientific literature to identify VL drug efficacy clinical trials will be conducted following the Preferred Reporting Items for Systematic-Reviews and Meta-Analyses (PRISMA) guidelines. This protocol has been designed following the PRISMA-P recommendations and was registered on PROSPERO (CRD42021284622) on 29th November 2021. This review builds on a previous systematic review that had identified clinical trials registered or published before January 2016. The original search strategies were revised in 2019 and the systematic library has been updated bi-annually since then. The current protocol is designed to describe the methodology used by IDDO for the future scheduled update of the VL clinical study library (the next search is scheduled for May 2022).

**Eligibility criteria**

All clinical studies in humans assessing any efficacy or safety outcome measure of antileishmanial drugs will be eligible for inclusion in this review. No restriction is placed on interventions/comparators used, outcomes measures adopted, or the language of publication. Table 1 provides the description of the Population, Intervention, Comparison, Outcomes and Study design (PICOS) used for the systematic review.
Table 1. PICOS used for defining the search and eligible studies.

<table>
<thead>
<tr>
<th>PICOS</th>
<th>Search String Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>• All clinical studies of Visceral Leishmaniasis in humans, assessing any efficacy or safety outcomes of an antileishmanial drug.</td>
</tr>
<tr>
<td></td>
<td>• Studies on cutaneous leishmaniasis, post-kala-azar dermal leishmaniasis (PKDL), canine VL, and those evaluating vaccines or prophylactic usage of drugs, studies describing vector control, net distributions, prevalence estimation, and diagnostic tests will be excluded.</td>
</tr>
<tr>
<td>Intervention</td>
<td>• The search strategy will be restricted to identify studies evaluating the efficacy of antileishmanial interventions; non-interventional studies are therefore not considered.</td>
</tr>
<tr>
<td>Comparator</td>
<td>• The search strategy and eligibility for inclusion are not restricted by the comparator used.</td>
</tr>
<tr>
<td>Outcomes</td>
<td>• The search strategy and eligibility for inclusion are not restricted by treatment outcomes given the primary aim is to understand the homogeneity/heterogeneity of all outcomes measured in VL.</td>
</tr>
<tr>
<td></td>
<td>• The following efficacy and safety outcomes of interest will be extracted from the studies identified: initial cure, relapse, loss to follow-up, post-kala-azar dermal leishmaniasis, death, adverse events and serious adverse events.</td>
</tr>
<tr>
<td>Study Design</td>
<td>• Non-intervention studies, case reports, retrospective studies and individual studies enrolling fewer than six patients will be excluded.</td>
</tr>
</tbody>
</table>

Search strategy
The following databases will be searched: PubMed, Ovid Embase, Scopus, Web of Science Core Collection, Cochrane Central Register of Controlled Trials, clinicaltrials.gov, WHO ICTRP, as well as IMEMR, IMSEAR, and LILACS from the WHO Global Index Medicus. The search will be run by an experienced librarian at the Bodleian Health Care Libraries, the University of Oxford, every six months to capture new studies registered or published during the period. Thesaurus headings for visceral leishmaniasis will be used where available in combination with phrase searches (OR) constructed for the title or abstract fields (“black fever”, “kala azar”, “visceral leishmaniasis”). These search terms will be combined with filters for randomised controlled trials for PubMed (the box 3.a Cochrane Highly Sensitive Search Strategy)\(^\text{15}\), Ovid Embase (an adapted version of the Box 3.e Cochrane Highly Sensitive Search Strategy)\(^\text{16}\), with adaptations of both filters applied to Scopus and the Web of Science Core Collection. The VL search terms will also be combined with thesaurus and free text (title or abstract fields) searches for antileishmanial drugs including Pentamidine, Ambisome, Amphotericin. A search filter will be applied to exclude animal studies, and searches will be limited to the relevant publication dates for that search period. Complete details on the search terminologies used for different databases can be found in the Extended data section\(^\text{18}\).

Study selection
Two reviewers will screen the studies identified in the search against the pre-specified eligibility criteria (Table 1) in a blinded fashion using Covidence software for systematic reviews\(^\text{20}\). Disagreements will be resolved through discussion between the two reviewers, where possible, or will be resolved by contacting a blinded third reviewer. Further details on the PICOS framework utilised for developing the search strategies and eligibility criteria for article screening is available in the Extended data section\(^\text{14}\).

Data extraction
Pre-existing variable and data dictionaries with extraction rules developed in the earlier iteration of the systematic review will be used, and data extraction will be conducted in the REDCap electronic data capture tool hosted at the University of Oxford\(^\text{12}\). Data on the following aspects of the studies eligible for inclusion will be extracted: study status, publication year, study design, location, case definition, diagnostic method, parasite species, age and number of participants, inclusion and exclusion criteria, including the eligibility for pregnant women, malnourished individuals and comorbidities such as human immunodeficiency virus (HIV) and tuberculosis. Information will also be extracted regarding the treatments assessed for each arm, dosing regimen, number of patients cured, number of relapses, duration of follow-up and the number of patients who completed follow-up. Furthermore, the extraction will also capture safety parameters like the presence of an adverse events monitoring and classification system, informed consent, Data Safety and Monitoring Board and reported number of adverse events and serious adverse events including the number of patients who died during the treatment or follow-up period. Lastly, parameters that would allow assessing the methodological rigour of studies such as information regarding sample-size estimation, randomisation method, allocation concealment and blinding of regimen or outcome assessment methodology will also be extracted. Full details of the variables extracted can be downloaded from IDDO VL-surveyor\(^\text{23}\).

Meta-analysis
A meta-analysis is planned for estimating the proportion of patients who develop relapse. This will be carried out using meta-analysis of single proportion using logit transformation. Heterogeneity will be quantified using \(F\) statistics and subgroup analyses will be carried out by geographical regions, drug regimens and other study characteristics. Sensitivity analysis will be carried out by the adjudicated risk of bias status in the.
studies included in the specific meta-analysis. Further meta-analysis may be carried out in the future on the following safety and efficacy endpoints of interest: the proportion of patients who reach initial cure status, who are lost to follow-up and those who develop post-kala-azar dermal leishmaniasis (PKDL) and on the following safety endpoints: death, adverse events. Further review on methodological aspects of study design, conduct, analysis, and reporting of clinical trials is anticipated in the future. All statistical analyses will be carried out using R software (R Project for Statistical Computing, RRID:SCR_001905).

Risk of bias assessment
The primary objective of this systematic review is to index all the clinical studies describing the efficacy of antileishmanial therapies and summarise the landscape of the clinical studies including the characteristics of the studies included and inclusion and exclusion criteria adopted. The analysis of this endpoint will be limited to providing a descriptive summary of trial characteristics, study design and interventions studied. Accordingly, assessment of meta-biases or the strength of the body of evidence represented within and across individual included records are not relevant for this primary research question. However, the biases related to the identification and inclusion of literature in this review and the totality of the evidence presented will be qualitatively discussed and assessed using the GRADE approach. For any formal meta-analysis that will be conducted on the safety and efficacy endpoints of interest such as the number of patients with subsequent relapse, initial cure, lost to follow-up and those who develop post-kala-azar dermal leishmaniasis (PKDL) or death, risk of biases in the studies included will be conducted using the Cochrane risk of bias tools. Non-randomised comparative studies will be assessed using the ROBINS-I tool and randomised studies will be assessed using the Risk of bias 2 (RoB 2) tool. Single-arm cohort studies will be assessed using the Newcastle-Ottawa scale.

Dissemination
The compiled database of eligible studies after completion of the six-monthly search updates will continue to be made publicly available through the IDDO VL-surveyor webpage.

Study status
182 published and/or on-going studies describing the efficacy of antileishmanial therapies have been indexed in the IDDO VL library of clinical studies as of November 2021. These studies are summarised and searchable in the VL Surveyor, hosted by IDDO. All studies have been fully extracted regarding relapse, initial cure and lost to follow up. The next literature search update as specified in this protocol is scheduled for May 2022.

Discussion
The limited generation and availability of clinical trial data for poverty-related neglected tropical diseases like VL necessitates that systematic reviews be updated regularly to capture emerging evidence regarding drug safety, efficacy and resistance described in the latest studies. Such practice is even more important in the case of VL as most of the trials are small (the median sample-size of a study arm is 32), and the number of failures (e.g. relapse) in any single study is small. Constantly identifying and adding information from new studies to the existing pool is, therefore, crucial for the generation of robust evidence and to avoid duplication of work. Maintaining a living systematic review as proposed in this protocol will update the existing database periodically, thus providing a unique resource that will continuously update the evidence base. This publicly available resource is intended to support the wider VL research community and save resources and time that would otherwise be required by groups planning to conduct new systematic reviews from scratch. Furthermore, the availability of easily accessible data from past studies can act as the baseline for comparing estimates from new studies and for the data collected by national control programs in the field.

The IDDO VL library of clinical studies is publicly available under the Open Database License (ODbL) after the completion of each round of review. This approach taken by IDDO serves as a global knowledge commons, as the easily and freely accessible repository can inform further meta-analyses based on factors such as drug class, geography, and a number of host and parasite characteristics. Maintaining this initiative will continue to help facilitate up to date evidence that can assist researchers and policymakers alike in combating this disease. The utility of previous iterations of this database has already been demonstrated, with use by the VL research community to understand different aspects of the disease including assessment of safety following antileishmanial therapies, characterisation of heterogeneity in the enrolled patient population and the design and conduct of VL clinical studies.

The initial goal of the IDDO VL library was to assess the feasibility of establishing an IPD platform to serve the research community. This goal is currently being realised as the 2017 review facilitated developing a VL data platform that currently hosts over 15,000 IPD from several studies identified from the review. The VL research community has come together to draft research proposals to harness the scientific potential of the IPD platform in exploring different risk factors of therapeutic and safety outcomes on a large scale that otherwise would not be possible through the aggregate data meta-analysis. The current living systematic review, therefore, not only serves as an active and comprehensive inventory of clinical studies in VL but also provides critical information to the VL community to identify research questions that would be feasible to answer using IPD meta-analysis. The promotion of these research activities remains critical as endemic countries are currently in different phases of disease control and elimination.

Data availability
Underlying data
No underlying data are associated with this article.
Extended data

This project contains the following extended data:
- Search strategy.docx
- PICOS screening strategy.docx

Reporting guidelines

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

Acknowledgments
An earlier version of this article can be found on ResearchSquare: https://doi.org/10.21203/rs.3.rs-1159661/v1.

References

Open Peer Review

Current Peer Review Status: ?

Version 1

Reviewer Report 22 June 2022

https://doi.org/10.21956/wellcomeopenres.19630.r50734

© 2022 Romero G. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gustavo Adolfo Sierra Romero
Núcleo de Medicina Tropical, Faculdade de Medicina, Universidade de Brasília, Brasília, Brazil

This is a very relevant protocol for a living systematic review dealing with clinical studies on visceral leishmaniasis. The protocol was elaborated following the PRISMA recommendations and is well-constructed with all the essential components for a systematic review. Please find below some suggestions for improvement of the clarity of the proposal:

1. The objectives could be better described. It seems that the first two of them are methodological steps more than objectives. The first one could be to describe and summarise the landscape of clinical studies on efficacy and safety of therapeutic interventions for visceral leishmaniasis. The second one is dispensable because extracting is not itself an objective, unless there's a peculiarity such as an innovative approach deserving special attention.

2. The PICOS table also deserves attention because it is expected a PICOS for the research question should guide the systematic review. In its current form it is more a list of inclusion or exclusion criteria than the main elements composing the structure of a research question. e.g. the population and study design are the inclusion and exclusion criteria for the clinical studies. Instead of that, the population should be: patients with VL, excluding those with PKDL, etc. The intervention should be the therapeutic interventions and not the search strategy that is specifically described in the text and supplementary material. The phrase in the outcome section: “The search strategy and eligibility for inclusion are not restricted by treatment outcomes given the primary aim is to understand the homogeneity/heterogeneity of all outcomes measured in VL.” is contradictory to the second phrase listing the outcomes that will be extracted from the studied. I suggest to exclude the first phrase. Finally, the study design should be stated as “Living systematic review”. It is important to remember that for the potential readers the PICOS for the research question is crucial and the eligibility criteria for the selection of studies should be stated in a separate table listed in an orthodox form.

Is the rationale for, and objectives of, the study clearly described?
Partly

Is the study design appropriate for the research question?
Partly

Are sufficient details of the methods provided to allow replication by others?
Yes

Are the datasets clearly presented in a useable and accessible format?
Not applicable

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical research, Leishmaniasis, Infectious Diseases, Public Health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.